Largest holders
| Holder | Type | Shares | Of the company | Source | As of |
|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Holder | 10.9M | 10.17%* | Form 13F | 30 Jun 2026 |
| BlackRock, Inc. | Holder | 9.1M | 8.54%* | Form 13F | 30 Jun 2026 |
| Vanguard Capital Management | Holder | 7.7M | 7.37% | Schedule 13G | 31 Mar 2026 |
| Dodge & Cox | Institution | 4.9M | 4.56%* | Form 13F | 30 Jun 2026 |
| State Street | Institution | 4.8M | 4.53%* | Form 13F | 30 Jun 2026 |
| Invesco | Institution | 3.9M | 3.69%* | Form 13F | 30 Jun 2026 |
| JPMorgan Chase | Institution | 3.8M | 3.54%* | Form 13F | 30 Jun 2026 |
| Leonard S. Schleifer, M.D., Ph.D. | Insider | 2.9M | 2.8% | Proxy statement | 24 Apr 2026 |
| Franklin Templeton | Institution | 2.8M | 2.60%* | Form 13F | 30 Jun 2026 |
| Geode Capital Management | Institution | 2.6M | 2.46%* | Form 13F | 30 Jun 2026 |
| Nuveen (TIAA) | Institution | 2.0M | 1.89%* | Form 13F | 30 Jun 2026 |
| Loomis Sayles & Co L P | Institution | 1.9M | 1.74%* | Form 13F | 30 Jun 2026 |
| Leonard S. Schleifer, M.D., Ph.D. | Insider | 1.7M | 95% Class A | Proxy statement | 24 Apr 2026 |
| George D. Yancopoulos, M.D., Ph.D. | Insider | 1.7M | 1.6% | Proxy statement | 24 Apr 2026 |
| T. Rowe Price | Institution | 1.5M | 1.43%* | Form 13F | 30 Jun 2026 |
| Morgan Stanley | Institution | 1.4M | 1.31%* | Form 13F | 30 Jun 2026 |
| Bank of America | Institution | 1.3M | 1.21%* | Form 13F | 30 Jun 2026 |
| Wellington Management | Institution | 1.3M | 1.19%* | Form 13F | 30 Jun 2026 |
| Norges Bank | Institution | 1.2M | 1.10%* | Form 13F | 30 Jun 2026 |
| Goldman Sachs | Institution | 1.2M | 1.09%* | Form 13F | 30 Jun 2026 |
Regeneron Pharmaceuticals has several share classes; each percentage is of the class the filer names.
